Indevus Pharmaceuticals Announces Completion Of Enrollment In Phase III Trial Of PRO 2000 Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced the completion of enrollment in Protocol MDP 301, a Phase III clinical trial of PRO 2000, the Company's candidate vaginal microbicide for the prevention of HIV and other sexually transmitted infections.
Source: www.medicalnewstoday.comNews From The Journal Of Clinical Investigation : Aug. 21, 2008 Molecular insight into one form of the bleeding disorder von Willebrand disease Individuals with von Willebrand disease (vWD) are at increased risk of bleeding compared with
healthy individuals, for example, they tend to bruise more easily and suffer more nosebleeds and bleeding gums.
Source: www.medicalnewstoday.comHighlights From Biology Of Reproduction, September 2008 Proteomes to unravel gonadotrophs Although the basic developmental lineage of pituitary gonadotrophs is known, it has been harder to associate specific changes in gene expression with maturation due to the limited cell population. In an article on p. 546 of the September 2008 issue of Biology of Reproduction, Feng et al.
Source: www.medicalnewstoday.comCHADD And AACAP Applaud Michael Phelps For Addressing Stigma Of ADHD Children and Adults with Attention-Deficit Hyperactivity Disorder (CHADD) and the American Academy of Child and Adolescent Psychiatry (AACAP) applaud Olympic gold-medalist Michael Phelps and his mother, Mrs. Deborah Phelps for educating the public about succeeding with attention-deficit/hyperactivity disorder (AD/HD). "Congratulations to Michael Phelps for winning eight Olympic gold medals.
Source: www.medicalnewstoday.comStudy Identifies Genetic Mutation That May Cause Malignant Hyperthermia After a surgical procedure, an 18-year old cheerleader from Florida died as a result of malignant hyperthermia, a condition triggered by certain anesthetics where the body heats up to dangerous levels. A study published in the September issue of Anesthesiology has identified a genetic mutation that could cause malignant hyperthermia (MH), this rare but potentially deadly condition.
Source: www.medicalnewstoday.comOffsetting Carbon Emissions: Smithsonian Works With Embera Community Thanks to a collaborative agreement signed between the Smithsonian Tropical Research Institute and the Organization for Unity and Development of the Community Ipeti-Embera, the Institute in Panama will offset its estimated carbon emissions for the next three years.
Source: www.medicalnewstoday.comInhibiting Blood Vessel Growth Shows Promise In Rat Model Of Deadly Brain Tumor In a landmark study, Medical College of Wisconsin researchers in Milwaukee report that
drugs used to inhibit a specific fatty acid in rat brains with glioblastoma-like tumors not only reduced new blood vessel growth and tumor size dramatically, but also prolonged survival. The study is the featured cover story of the August, 2008 Journal of Cerebral Blood Flow & Metabolism.
Source: www.medicalnewstoday.comGene Therapy Anti Cancer Work Featured In Scientific American Scientific American magazine focused on two University of Alabama at Birmingham (UAB) Comprehensive Cancer Center researchers in a news story on experimental next-generation anti-cancer therapies. David T. Curiel, M.D., Ph.D., is a UAB professor of
medicine and director of the human gene therapy division, and Ronald Alvarez, M.D.
Source: www.medicalnewstoday.comAcademy Specimen Collection Benefits From Mellon Grants The Academy of Natural Sciences has announced the receipt of two grants from The Andrew W. Mellon Foundation in connection with the museum's world-renowned specimen collection. A $99,000 grant will fund the digitization of about 9,000 sheets of mostly Latin American and African type specimens of plants, some dating to before 1850.
Source: www.medicalnewstoday.com
# posted by Network @ 12:00 PM
